Publication | Open Access
Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database
46
Citations
38
References
2021
Year
Neutropenia, superinfections, reactivation of latent infections, hepatitis, and cardiac abnormalities were common ADEs observed that necessitate proper monitoring and reporting.
| Year | Citations | |
|---|---|---|
Page 1
Page 1